Medline (NASDAQ:MDLN) Research Coverage Started at Mizuho

Mizuho began coverage on shares of Medline (NASDAQ:MDLN) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $48.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Piper Sandler started coverage on shares of Medline in a research report on Monday. They set an “overweight” rating and a $50.00 target price on the stock. Sanford C. Bernstein initiated coverage on shares of Medline in a report on Monday. They issued an “outperform” rating and a $49.00 price target on the stock. Stifel Nicolaus initiated coverage on Medline in a research report on Monday. They set a “buy” rating and a $46.00 price objective for the company. Evercore ISI started coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Robert W. Baird initiated coverage on Medline in a report on Monday. They set an “outperform” rating and a $48.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Medline has a consensus rating of “Moderate Buy” and a consensus price target of $46.70.

Medline Stock Up 1.3%

Medline stock opened at $43.41 on Monday. Medline has a 1-year low of $34.89 and a 1-year high of $45.50.

Insider Activity

In other news, Director Charles N. Mills bought 2,579,310 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the transaction, the director owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This represents a -1,870.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.